Primer: Sichuan Biokin Pharmaceutical (688506 CH) - Apr 2026
Sichuan Biokin Pharmaceutical is a biopharmaceutical company at a pivotal stage of transformation, shifting from a traditional generics and...
144 Views
China Healthcare Weekly (Nov.16) - Crazy Healthcare IPOs, Don't Bet on BD, Biokin HK IPO Delayed
​Investors're advised to focus on technical route over new BD deals from Chinese companies. Investors need to remain rational about healthcare...
433 Views
Pre-IPO Sichuan Biokin Pharmaceutical (PHIP Updates) - Some Points Worth the Attention
Biokin’s high-end IPO pricing (HK$389) shows a premium over A-shares (RMB352.3). Lower-end pricing (HK$347.5) is only discounted by 10%, far lower...
513 Views
Sichuan Biokin Pharmaceutical IPO: Well-Positioned to Ride Oncology Focused Global ADC Wave
Sichuan Biokin Pharmaceutical has launched HK IPO to raise ~$430M by offering 8.6M shares at HK$389 per share. Subscriptions will close on November...
645 Views
Sichuan Biokin A/H Listing: Stretched Valuation
​China's Sichuan Biokin plans to raise $432 million through a Hong Kong listing. We look at the deal terms and are of view that the valuation is...
262 Views